DaVita (NYSE:DVA) Stock Rating Lowered by Zacks Research

Key Points

• Zacks Research downgraded DaVita from a "strong-buy" to a "hold"; the street consensus is also a Hold with a $155.80 average target (1 Buy, 5 Hold, 1 Sell).
• DaVita beat the latest quarter with $3.40 EPS vs. $3.24 expected and $3.62B revenue (up 9.9% year-over-year) and set FY 2026 guidance of 13.60–15.00 EPS.

DaVita (NYSE:DVA - Get Free Report) was downgraded by equities researchers at Zacks Research from a "strong-buy" rating to a "hold" rating in a report issued on Monday,Zacks.com reports.

A number of other brokerages also recently weighed in on DVA. Barclays boosted their target price on DaVita from $143.00 to $158.00 and gave the stock an "equal weight" rating in a research note on Tuesday, February 3rd. TD Cowen restated a "hold" rating on shares of DaVita in a research note on Tuesday, February 3rd. Weiss Ratings restated a "hold (c)" rating on shares of DaVita in a research note on Monday, December 29th. Wall Street Zen upgraded DaVita from a "hold" rating to a "buy" rating in a research note on Saturday, February 21st. Finally, UBS Group upped their price objective on DaVita from $186.00 to $190.00 and gave the company a "buy" rating in a research note on Wednesday, February 4th. One equities research analyst has rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $155.80.

DaVita Stock Down 0.3%

Shares of NYSE DVA opened at $149.65 on Monday. DaVita has a twelve month low of $101.00 and a twelve month high of $159.42. The stock's 50 day moving average price is $146.37 and its 200-day moving average price is $129.05. The company has a market capitalization of $10.00 billion, a PE ratio of 15.10, a PEG ratio of 0.51 and a beta of 0.92.

DaVita (NYSE:DVA - Get Free Report) last announced its earnings results on Monday, February 2nd. The company reported $3.40 earnings per share for the quarter, topping analysts' consensus estimates of $3.24 by $0.16. DaVita had a negative return on equity of 413.18% and a net margin of 5.47%.The firm had revenue of $3.62 billion for the quarter, compared to the consensus estimate of $3.51 billion. During the same quarter in the previous year, the business earned $2.24 EPS. The company's revenue was up 9.9% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. As a group, research analysts expect that DaVita will post 10.76 EPS for the current fiscal year.

Institutional Investors Weigh In On DaVita

Several institutional investors have recently made changes to their positions in DVA. Elevation Wealth Partners LLC lifted its position in shares of DaVita by 147.3% during the fourth quarter. Elevation Wealth Partners LLC now owns 277 shares of the company's stock worth $31,000 after acquiring an additional 165 shares in the last quarter. Caitlin John LLC purchased a new stake in shares of DaVita during the fourth quarter worth $34,000. Sankala Group LLC purchased a new stake in shares of DaVita during the fourth quarter worth $39,000. Canada Pension Plan Investment Board purchased a new stake in shares of DaVita during the second quarter worth $43,000. Finally, Kestra Advisory Services LLC purchased a new stake in shares of DaVita during the fourth quarter worth $45,000. Hedge funds and other institutional investors own 90.12% of the company's stock.

DaVita Company Profile

DaVita Inc NYSE: DVA is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.